Alex Gorsky on drug development
From Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim · · Recursion
“I think there's extraordinary promise you know to Dean's earlier comment across almost every domain that we touch and and if anything I would uh kind of implore everybody in this room to think about this not just as is this going to be an impact on drug Discovery drug development but how does it impact our entire system of the way we look at bringing Therapeutics to Market uh because one will implicate the other and if we don't think about as we're as we're you know selecting new sites as we're designing new um molecules what impact that that's going to have an our ability to actually create manufacture and Supply these as we as we think about creating new drugs for perhaps more specific patient populations how are we going what's the commercial model going to be and how can we utilize some of these same tools to ensure that we can get access in a way that is commensurate with our overall goals”
On , Alex Gorsky, Former Executive Chairman & Chief Executive Officer at Johnson & Johnson, spoke about drug development during Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim on Recursion.
About Alex Gorsky
Alex Gorsky, former Executive Chairman and CEO of Johnson & Johnson, participated in a keynote discussion at the LSI USA '24 Emerging Medtech Summit in May 2024. During the conversation, he argued that the traditional model of pricing medical devices with a small performance difference at a significantly higher cost "is not going to work." He stated that healthcare spending will increase over the next decade due to demographic shifts, and he described this as "not a bad thing" for a developed society. Gorsky also warned that if the industry does not focus on ensuring broad access to technology, "countervailing political forces" could change the healthcare ecosystem. He noted that large-scale M&A is "quite challenged" and expressed concern about that trend. Gorsky predicted that enabling technologies like cloud, connectivity, and AI will become the focus of medtech within ten years, and he advised entrepreneurs and investors to "think differently" about enabling the next generation of healthcare. Earlier, during the COVID-19 pandemic in 2020, Gorsky discussed Johnson & Johnson's development of a vaccine on a not-for-profit basis, stating that the company aimed to provide broad access. He emphasized the importance of relying on "data, science, and well-established regulatory guidelines" during a politicized time. In a 2018 interview, Gorsky described leading Johnson & Johnson with a "start-up mode" mindset, stressing the need for constant reinvention. He also discussed the importance of the company's Credo, a set of principles he said serves as a "moral compass," and noted that all employees had participated in "Credo challenge" sessions to discuss its relevance. In a 2013 interview, Gorsky identified significant organizational and people changes as among the most challenging decisions he faced, and he said he evaluates leaders based on their performance, their track record in developing future leaders, and how they develop talent with the Credo in mind.